[A case of angiosarcoma of the scalp with severe fluid retention after administering docetaxel].

Abstract

A 7 3-year-old man with angiosarcoma was treated with concurrent chemoradiotherapy, using docetaxel (25mg/m(2) weekly). While the size of the tumor reduced rapidly, fluid retention, considered as an adverse effect of docetaxel, appeared at the cumulative dose of 325mg/m(2). He required chest drainage for prolonged pleural effusion. Though fluid retention due to docetaxel is infrequently reported in Japan, it may lead to severe illness and require discontinuation of chemotherapy. When we administer docetaxel over a prolonged period, we should be aware of this adverse effect.

• Authors: Ryoichi Namba, Jun Kanazawa, Yusuke Yamamoto, Shusaku Itou, Takeshi Nawa
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 38 Issue 5 Pg. 807-10 (May 2011) ISSN: 0385-0684 [Print] Japan
• PMID: 21566442 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents
• Taxoids
• Docetaxel

Topics

• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Biopsy
• Combined Modality Therapy
• Docetaxel
• Drainage
• Head and Neck Neoplasms (drug therapy, pathology, radiotherapy)
• Hemangiosarcoma (drug therapy, pathology, radiotherapy)
• Humans
• Male
• Pleural Effusion, Malignant (chemically induced)
• Scalp (pathology)
• Skin Neoplasms (drug therapy, pathology, radiotherapy)
• Taxoids (adverse effects, therapeutic use)
• Tomography, X-Ray Computed